Taysha Gene Therapies Pre-Tax Profit Margin 2020-2024 | TSHA

Taysha Gene Therapies pre-tax profit margin from 2020 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Taysha Gene Therapies Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2024-09-30 $0.01B $-0.02B -230.00%
2024-06-30 $0.01B $-0.11B -876.92%
2024-03-31 $0.01B $-0.12B -842.86%
2023-12-31 $0.02B $-0.11B -700.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.506B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00